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It is well known that the insect cell-baculovirus expression vector system
(IC-BEVS) can be used for the production of various proteins of interest
and virus-like particles (VLPs). In the past, many higher order proteins and
protein complexes like antibodies (zu Putlitz et al., 1990), viral vectors (Au-
coin et al., 2006) and VLPs (Pushko et al., 2005, 2010) have been produced
using this system. For the production of recombinant proteins of interest or
VLPs, one or more baculovirus constructs, each carrying one (monocistronic)
or more (polycistronic) gene(s) of interest can be introduced to insect cells.
Three common expression systems for protein production mainly include in-
fecting insect cells with a number of baculovirus constructs each carrying a
gene of interest (coinfection), infecting insect cells with a single baculovirus
construct carrying multiple genes of interest (coexpression), or a combination
of the two systems (Sokolenko et al., 2012). Although coexpression is the ulti-
mate goal, there are many reasons coinfection is still used. Coinfection allows
a degree of flexibility that is not as easily achieved through coexpression. The
hypothesis behind this work is that, the virus ratios or the population dis-
tribution remains constant upon repeated propagation. Here, we are seeking
to avoid coinfection at larger scale by amplifying viruses together at smaller
scale. By infecting cells with baculovirus coding for reporter proteins, eGFP
and mKate2, at high and low MOIs we can track the virus population be-
ing amplified and be confident that the ratios are preserved or will require
adjustment upon repeated amplification. We can then use this knowledge
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to improve the production of influenza A VLPs, a more industrially relevant
system.
Different assays and/or techniques were used to assess the virus popula-
tion distribution over repeated propagation at high or low MOI, in addition
to purification and analysis of influenza VLPs. It was concluded that re-
peated amplification at high MOI changed the population distribution, and
also resulted in significant drops in the infectious virus titer. Amplifications
at low MOI improved the virus titer, and not much variation was observed
in the distribution over subsequent passaging. That being said, it was found
that ultracentrifugation alone did not have the resolution to purify VLPs,
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The production of recombinant proteins and virus-like particles (VLPs) using
the insect cell-baculovirus expression vector system (IC-BEVS) has become
a promising platform owing to their ease of use and versatility. Development
of a number of transfer vectors, simplified recombinant virus isolation and
quantification methods and improvements in cell culture technology have
made this system easy to use, safe and readily scalable (Kost et al., 2005).
The limited host-range in which these baculovirus can replicate, capability
of the baculovirus to accept multiple large insertions and high protein yields
makes the system a great choice for recombinant protein production (George,
2016). Ability of insect cells to perform post-translational modifications in-
cluding glycosylation (James et al., 1996), phosphorylation (Héricourt et al.,
2015) and disulfide bond formation (Hodder et al., 1996), makes BEVS a
platform of choice for production of foreign protein that requires such mod-
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ifications (Reed and Muench, 1938). A complex and sophisticated series of
tightly temporally regulated events takes place upon infection of insect cells
with baculovirus (George and Aucoin, 2015). IC-BEVS provides a number
of advantages including high levels of expression, mammalian cells like post-
translational modifications and inherent safety during manufacture and of
the final product as reviewed by Sokolenko et al., 2012. Moreover, the lack
of human infectitious viruses in insect cells (Summers, 2006) and inability
of baculovirus to grow in or infect mammalian cells (Sokolenko et al., 2012)
makes it advantageous for production of therapeutic proteins.
On the basis of using multiple baculoviruses each carrying a foreign gene
(monocistronic baculovirus) or a single baculovirus carrying multiple for-
eign genes (polycistronic baculovirus) to infect insect cells, the three most
common infection strategies include coinfection (infection with a number of
baculovirus constructs each expressing a gene of interest), coexpression (in-
fection with one baculovirus construct expressing multiple genes of interest)
and a combination of the two (Sokolenko et al., 2012). The introduction of
viruses to cell cultures by an infection strategy, and the subsequent steps
comprising of virus entry into cells, viral gene replication and assembly, and
virus budding is known as virus amplification/propagation/passaging. It is
believed that while coinfection is more suited to determine the levels of indi-
vidual genes required to make a desired product, coexpression plays a more
important role for large scale production. That being said, the flexibility of-
fered by coinfection to control the ratios of different proteins needed to form
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a particular product can be successfully exploited at a small scale.
Figure 1.1: Schematic of a possible scale-up process.
There are many reports present in literature that exploit the benefits of
the IC-BEVS for the production of virus-like particles. These VLPs, which
are basically derived from the structural components of a virus of inter-
est, can induce the same immune response in host as that of a virus. In
other words, VLPs are similar to a virus except it does not contain the viral
genome. Production of VLPs in multiple cell culture systems, such as mam-
malian cells (Wu et al., 2010; Thompson, 2013) and insect cells using BEVS
(Lopez-macias et al., 2011), and their non-replicative nature makes them a
safer alternative for many applications including vaccination. According to
the World Health Organization (WHO), influenza A virus infection, that re-
sults in acute respiratory tract infection, causes around 300,000 to 500,000
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deaths annually worldwide (Organization, 2010). Mutation in the major
glycoprotein hemagglutinin (HA) is mainly responsible for poor control of
the infection with immunization. New vaccine strategies need to include
immunization with viral antigens in addition to HA. These antigens should
induce a broadly cross-reactive immunity capable of protecting vaccine recipi-
ents from antigenic heterovariants by including influenza viral neuraminidase
(NA) and/or matrix protein (Johansson and Eichelberger, 2010). Influenza
A VLPs provide better immune response as compared to inactivated or live
attenuated vaccines (Pushko et al., 2005, 2010; Bright et al., 2007). Also,
GAG-based influenza VLPs containing influenza proteins have been reported
to exhibit sturdy vaccine protection (Haynes et al., 2009). Although the use
of IC-BEVS is quite popular, the production of VLPs using this system needs
to be optimized for industrial scale.
The driving hypothesis behind this work is that when two viruses are
amplified together in cell culture, the ratio of the two virus populations is
maintained over repeated propagation. Although coinfection seems to be the
choice for small scale production owing to the additional degree of freedom
it provides, for industrial scale its use is usually minimized. In this study
we start with coinfection to determine the individual levels of each gene at
a smaller scale and try to track the population of viruses after repeated
amplification and make sure the ratio of viruses are maintained or if some
modifications are needed upon amplification. Using this information we can
explore an amplification process which starts with multiple viruses, each
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carrying a gene of interest, and then use the virus stocks from the coinfected
cultures for subsequent infections. With some modifications, this can then
be extended for influenza A VLP production.
The first chapter of this thesis is a general introduction to IC-BEVS, in-
fection strategies and influenza VLPs. This is followed by a literature review
relevant to the work presented in the thesis and a chapter outlining all the ma-
terials and methods used in this work. Chapter 4 presents a simple system
where two baculovirus constructs carrying the gene for eGFP (a green fluo-
rescent protein, GFP) or mKate2 (a red fluorescent protein, RFP) were used
to establish a baseline. The information gathered from the GFP/RFP work
was then expanded to a more industrially relevant system of proteins that
can be used for influenza A VLP production, and the results are presented in
Chapter 5. An overall conclusion of this work and some recommendations





Baculoviruses are enveloped DNA viruses with a very narrow host range
within arthropod invertebrates (Lu and Miller, 1997). They are divided into
the nucleopolyhedroviruses (NPVs), which can form occlusion bodies com-
posed of one or more virions encapsulated in a polyhedrin protein matrix,
and the granuloviruses (GV), which can form occlusion bodies containing a
single virion encased in a granular protein matrix (Funk et al., 1997). Bac-
uloviruses can exist in one of two forms during their life cycle: occluded
form (responsible for transmission between hosts) and budded form (respon-
sible for transmission within a host). Baculoviruses are 300 nm in length, 50
nm in diameter, with a circular supercoiled double stranded DNA genome
(Rohrmann, 2019). Autographa californica multiple nucleopolyhedrovirus
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(AcMNPV) and Bombyx mori nucleopolyhedrovirus (BmNPV) are the two
most widely studied baculoviruses for production of recombinant proteins
and VLPs.
Figure 2.1: Baculovirus life cycle.
(Adapted from (George, 2016))
The baculovirus infection cycle is divided into three phases: the early
phase, the late phase and the very late phase. The early phase, also known
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as virus synthesis phase, occurs from 0.5 to 6 hours post infection (Chisholm
and Henner, 1988) and includes two sub-phases (immediate early and de-
layed early) during which the virus prepares the infected cells for viral DNA
replication. The cells start to produce extracellular virus (EV), also called
non-occluded virus (NOV) or budded virus (BV) in the late phase or the
viral structural phase, between 6 to 12 hours post infection. Late genes
coding for viral DNA replication and viral assembly are expressed with the
peak release of EV between 18 to 36 hours after infection. The very-late
phase, also known as the viral occlusion protein phase, marks the expression
of polyhedrin and p10 genes, formation of occluded virus (OV) or occluded
bodies (OB) or polyhedral inclusion bodies (PIBs) and beginning of cell lysis
(Kelly et al., 2007). Although the origin of baculovirus DNA replication is
not known clearly, some reports suggests that the homologous regions are the
DNA replication initiation sites (Kool et al., 1993), while others claim that
initiation can occur at other sites (Habib and Hasnain, 2000). The DNA
replication in baculovirus occurs either by rolling circle mechanism (Volk-
man and Oppenheimer, 1997) or by recombination (Okano et al., 2007) and
requires several baculovirus gene products.
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Figure 2.2: Morphology of budded baculovirus.
When a baculovirus is used as an expression vector for in vitro infection,
the naturally occurring polyhedrin (polh) gene in a wild type baculovirus
is usually replaced with recombinant gene(s) of interest. However, other
early and late promoters are being investigated for foreign gene expression
(George, 2016). The polyhedrin and p10 promoters are associated with large
production of recombinant protein(s) in the very-late phase of baculovirus
infection. The metabolic condition of culture and growth medium used as
well as the insect cell line and baculovirus strain used, can control the timing
of baculovirus infection cycle.
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2.2 Insect cell culture
As early as the 1930s insect cell lines were initiated and used for replication
of insect baculoviruses and arboviruses (Arif and Pavlik, 2013). Insect cells
usually do not carry any infectious human virus and especially retrovirus
(Summers, 2006). Many continuous cell lines such as Spodoptera frugiperda
cells (Sf9 or Sf21 clones) and Trichoplusia ni cells (High Five clone) have been
isolated and characterized for the production of biologics (Mena and Kamen,
2011). The cell lines grow well in suspension thus allowing for recombinant
protein production in large scale bioreactors, and were rapidly developed
for suspension culture and serum free media to minimize production costs
(Maranga et al., 2003).
Grace’s supplemented medium (TNM-FH) developed in the 1960s has
been a traditional medium of choice for in vitro insect cell culture (Grace,
1962). Other serum/hemolymph dependent media such as, IPL-41 and TC-
100, and serum free media such as Sf-900 II SFM, Sf-900 III SFM and EX-
PRESS FIVE SFM have been developed thereafter (Chan and Reid, 2016;
Bauer and Schnapp, 2007). Optimized second generation serum free media
such as Sf-900 II and III SFM with lot-to-lot consistency, reduced down-
stream processing complexity and low cost, have facilitated large scale pro-
duction of recombinant proteins (Zhang et al., 1992).
The three most common insect cell lines, Sf9, Sf21 and High Five, used
in research are derived from lepidopteran insects (Arunkarthick et al., 2017)
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with Sf9 and Sf21 cells being derived from pupal ovarian tissue of the fall
armyworm, Spodoptera frugiperda (Wickham et al., 1992) and High five cells
from the ovarian tissues of the cabbage looper, Trichoplusia ni (Hong et al.,
2015). The main components of insect cell maintenance media consists of a
mixture of carbohydrates, amino acids, vitamins, growth factors, trace ele-
ments, salts, metabolic precursors and hormones. Different cell lines require
various concentrations and combinations of these constituents (Arunkarthick
et al., 2017). The ideal temperature for maintenance is between 26 to 28
◦C, with a lower temperature resulting in decreased growth rate and a tem-
perature higher than 30 ◦C leading to lower viability (Arunkarthick et al.,
2017).
In serum free and protein free medium cultures, insect cells have a fast
specific growth rate. Running batch and fed-batch bioreactors with cells den-
sities reaching high levels is quite straightforward and robust till the culture
conditions are tightly monitored and controlled. Ability of insect cells to
grow in serum free medium is highly beneficial as it eliminates the chances
for occurrence of adventitious viruses thus reducing the need for more inten-
sive purification processes (Vicente et al., 2011). The requirement for annual
adjustments to influenza vaccine makes the insect cell-baculovirus expression
vector system (IC-BEVS) suitable for the production of influenza VLPs (Cox
and Hollister, 2009).
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2.3 Protein production platform
Different platforms such as bacteria, yeast, plant cells, mammalian cells and
insect cells are available for recombinant protein production. Egg-based tech-
nology has been used for a long time for the production of inactivated and
live attenuated influenza vaccines (Milián and Kamen, 2015). In the bio-
pharmaceutical industry, production of therapeutic proteins or vaccines using
mammalian cell culture technology is well established (Le et al., 2010). Sev-
eral mammalian cell lines such as MDCK (Madin Darby canine kidney cells)
(Rimmelzwaan et al., 1998), PER.C6 (human embryonic retinal cells) (Pau
et al., 2001), Vero (African green monkey derived kidney cells) (Barrett et al.,
1998) and HEK293 (human embryo kidney cells) (Le et al., 2010) have been
explored for the production of influenza particles. Optaflu/Flucelvax R© (No-
vartis) vaccine approved by the FDA in 2012 is a trivalent vaccine produced
in MDCK cells (Doroshenko and Halperin, 2009). PerflucelTM is another in-
fluenza vaccine produced in Vero cells, formulated with inactivated H1N1,
H3N2 and influenza B virus (Agency, 2012).
Cervarix, a human recombinant papillomavirus VLP cancer vaccine, was
successfully produced using the insect cells-baculovirus expression vector sys-
tem. A well-accepted safety profile of insect cells has led to their considera-
tion for commercial vaccine production (Vicente et al., 2011). A recombinant
baculovirus carrying a gene of interest can be designed faster thus resulting
in shorter turnaround periods when compared to other production methods
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(Cox and Hashimoto, 2011).
2.4 Advantages of the BEVS
The baculovirus expression vector system has become a versatile and pow-
erful eukaryotic vector system for recombinant protein production, since its
introduction in 1983 (Smith et al., 1983a). The IC-BEVS works by inserting
one or more gene(s) of interest into a baculovirus genome, using a transfer
plasmid, under the control of a baculovirus or insect promoter sequence and
at a site that does not interfere with the baculovirus replication (George,
2016). The ideal sites for insertion of the gene(s) of interest are situated
downstream of the very strong very late baculoviral p10 or polyhedrin pro-
moters, which leads to very high expression levels (Smith et al., 1983b).
BEVS offers a number of advantages over other expression vector systems.
The restricted host range and non-pathogenicity to mammals and plants,
makes baculovirus an ideal choice (Fuxa, 1991). The requirement of helper
cell lines or helper viruses is eliminated as all the genetic information can
be contained in the baculovirus genome. Recombinant products produced
using BEVS can be easily scaled up for large scale production. High levels of
recombinant gene expression can be achieved using this system (Sokolenko
et al., 2012) along with the mammalian like post-translational modification
capacity of insect cells.
The baculovirus has limited permissive cell lines for infection. The BEVS
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has the advantage of lower risks of contamination with human adventitious
agents over mammalian platforms and the ability to provide eukaryotic pro-
tein modifications including N-glycosylation (Toth et al., 2014). Expression
systems such as bacteria and yeast are known to achieve higher yields, but
they do not match the degree of complexity (expression of multiple/different
gene(s) of interest) required for VLPs that can be achieved with IC-BEVS
(Vicente et al., 2011). The product yields obtained are significantly higher
using IC-BEVS when compared to egg-based or mammalian cell based VLP
production and the production time is also reduced to 12 weeks (James,
2009).
2.5 Coinfection versus coexpression using the
BEVS
Expression of one or more foreign proteins for the production of a protein
complex can be achieved by one of the three most common infection strategies
using IC-BEVS: coinfection, coexpression or a combination of both. On
one hand, coinfection, using multiple virus constructs each carrying a gene
of interest, provides an additional degree of flexibility that is beneficial for
early exploratory work. On the other hand, coexpression, using a single
virus construct carrying all the genes of interest, is preferred at the larger
scale owing to the reduced number of different virus constructs required for
infection (George, 2016).
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The choice of infection strategy is critical for the production of a desired
protein or protein complex. Some groups have focused on coexpression for
the production of protein complexes (Road, 1995; George et al., 2015). This
expression strategy not only reduces the total amount of baculoviruses, but
also decreases the number of possible combinations of baculoviruses that can
be found in one cell (Sokolenko et al., 2012). Coexpression using polycistronic
baculovirus allows the desired production of all foreign proteins in every in-
fected cell. The expression ratios in such cases can be controlled and adjusted
by manipulating the promoters that control the levels of protein expression
(Road, 1995). However, the use of only very strong very late p10 and poly-
hedrin promoters to drive expression does not provide much opportunity to
tailor expression ratios within the cell. George et al., 2015 demonstrated
that the use of alternative promoters to control the timing and expression of
foreign proteins may prove to be a better alternative to modify coexpression.
Many other groups in the past have exploited coinfection due to the abil-
ity of insect cells to be infected by multiple baculovirus constructs, as the
primary expression strategy for the production of complex products (Aucoin
et al., 2006; Mena et al., 2010; Meghrous et al., 2005). For coinfection the
crucial parameters of interest are multiplicity of infection (MOI) and time
of infection (TOI) (Sokolenko et al., 2012). By varying the MOI, that is
the ratio of infectious baculovirus to the number of viable insect cells at the
time of virus addition, the infection conditions can be controlled. Coinfection
offers the advantage of investigating the ratio of each gene required for the
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optimal production of a desired product complex by altering the MOI of indi-
vidual virus vectors carrying a foreign gene. The work by Aucoin et al., 2006
demonstrated how coinfection strategies with a combination of monocistronic
(virus vector carrying one foreign gene) and polycistronic (virus vector carry-
ing multiple foreign genes) baculoviruses led to differences in yield depending
on baculovirus ratios selected, thus highlighting the necessity to understand
the relationship between baculovirus constructs to optimize the coinfection
strategy. The inherent instability of large baculovirus constructs containing
multiple genes makes process scale-up unfavourable, projecting the impor-
tance of coinfection strategy (Aucoin, 2007).
2.6 Defective interfering particles and virus
amplification
Defective interfering particles (DIPs) are spontaneous deletion mutants of
viruses that can infect insect cells, but not complete the replication cycle,
and replicate at the cost of the parent virus. It has been observed that the
growth of viruses in vitro, as well as the establishment of a persistent infection
is affected by DIPs (Kirkwood and Bangham, 2006). Multiple passage of
baculovirus in cell culture medium, especially at high MOI results in the
accumulation of DIPs.
These defective particles are known to interfere with the helper virus
replication, lack considerable portions of the genome and cause the passage
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effect during serial passaging in insect cell cultures. The presence of DIPs
with a major genomic deletion upon serial passage of AcMNPV-E2 in Sf21
cells has been observed (Kool et al., 1991). Based on the above mentioned
work by Kool and group (1991), another study demonstrated the presence
of DIPs lacking 43% of the viral genome in low passage AcMNPV-E2 virus
stocks and in polyhedra, but not in AcMNPV isolate obtained prior to cell
culture passaging (Pijlman et al., 2001). It has been postulated that the rapid
generation of DIPs is an intrinsic property of baculovirus infection in insect
cell culture, involving several recombination steps (Pijlman et al., 2001).
Production of recombinant protein and baculovirus, after repeated virus
amplification in insect cells at high MOI, is usually accompanied by the
appearance and accumulation of DIPs (Wickham et al., 1991). The phe-
nomenon of passage effect, that is, generation of defective particles upon
recurrent passaging at high MOI in insect cells, complicates the scale-up of
baculovirus and recombinant protein in vitro (Pijlman et al., 2001). On the
other hand, during a low MOI infection all the cells in the culture are not
infected and instead consists of multiple infection cycles. A low MOI infec-
tion results in some cells receiving replicative virus, some receiving DIPs and
others not receiving any virus particles (Wickham et al., 1991). Several stud-
ies have shown the use of low MOI for virus amplification, hence reducing
the passage effect. For the production of self-forming Porcine parvovirus-like
particles using the IC-BEVS, a low MOI was used to avoid an additional virus
amplification step and to minimize accumulation of DIPs (Maranga et al.,
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2003). A study on the occurrence of DIPs within high passage AcMNPV,
interference with recombinant protein and infectious virus production was
presented using three insect cell lines. They observed significant reductions
in the specific productivity of a recombinant protein with MOI over 0.01
pfu/cell (Wickham et al., 1991).
In addition to cell line and media used for production, factors such as
pH, temperature, dissolved oxygen and, infection and harvest parameters
(including MOI, TOI and time of harvest (TOH)) are critical for optimal
baculovirus vector production process. Current production processes relies
on cultures infected at low densities of 1 to 3 x 106 cells/ml at low MOIs
(Aucoin et al., 2010). High MOI (> 3 pfu/cell) infections results in the
entire cell population being simultaneously infected and is referred to as syn-
chronous infection. In contrast low MOI (<< 1 pfu/cell) infections leads to
asynchronous infection where only a portion of the overall cell population is
infected. Aucoin et al., (2010) described the dynamics of low MOI infection
in four steps. The first step involves two cell populations being observed
with one infected population and one uninfected population, following that
the infected population produces progeny virus and the uninfected popula-
tion keeps growing until additional viruses are produced after the primary
infection. The final step involves infection of the non-infected population af-
ter a time period by the progeny viruses that bud from the primary infected
cells. To minimize the production of DIPs, which interferes with process
productivity and baculovirus quality, a low MOI is preferred for virus ampli-
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fication (Pijlman et al., 2003). It has been reported that the accumulation
of non-homologous repeated origin of replication regions (non-hr ori) causes
defective particle formation, and the deletion of these regions from the viral
DNA can help to prevent the accumulation of DIPs (Pijlman et al., 2003).
2.7 Influenza A virus and VLP
2.7.1 Influenza A virus
Influenza A viruses belonging to the Orthomyxoviridae family are enveloped
RNA viruses with the genome divided into 8 negative sense single stranded
RNA fragments (Krammer and Schinko, 2010). Five of the single stranded
RNA fragments encode a single protein each and the other three encode
two proteins each (Bouvier and Palese, 2008). The major glycoproteins and
antigens of influenza A virus, HA and NA, are responsible for binding to
cellular receptors of host cells and mediating the release of newly synthesized
particles from the host cell surface, respectively (Nayak et al., 2009). The
matrix protein, M1, of the influenza virus binds the viral RNA and along
with the HA and NA forms the structural component of the virus. The
neuraminidase (NA) surface protein releases newly formed virus from cell
surfaces by cleaving the sialic acid residues that binds the cell to the HA
protein. The HA glycoprotein, which is used in this project, is present as a
trimer on the surface of the virus. A 17 amino acid residues is followed by a
511 amino acid extracellular domain, which is further followed by a helical 21
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amino acid transmembrane domain and finally a 16 amino acid cytoplasmic
tail domain (Winter et al., 1981). Other viral components and non-structural
proteins of the virus are involved in virus infectivity and transmission of host
cells.
Figure 2.3: Influenza virus morphology and symptoms of flu.
2.7.2 Production of influenza VLPs
Influenza A VLPs have been produced in mammalian and insect cells previ-
ously. The baculovirus expression vector system is gaining popularity for the
production of influenza VLPs mainly due to the lack of sialylation in insect
cells, which prevents the binding of HA proteins present on the surface of in-
fluenza VLPs to the cells. This eliminates the need for viral NA to cleave the
VLPs from the cell surface, unlike in mammalian cells (Mena et al., 1999).
The first multi-subunit influenza VLP was produced in BEVS using a bac-
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ulovirus coexpressing HA, NA, M1 and M2 proteins (Latham and Galarza,
2001). The production of nontransducing influenza VLP in insect cell cul-
ture through the simultaneous expression of influenza HA, NA, M1 and M2
in a single baculovirus resulted in the release of particles in the supernatant
that were morphologically similar to influenza virions (Latham and Galarza,
2001; Cox, 2008). Another work showed that coinfecting insect cells with
monocistronic baculoviruses coding for HA or M1 proteins led to the pro-
duction of VLPs comprising of HA and M1, and which provided protective
immunity from influenza virus (Quan et al., 2007). Simultaneous expres-
sion of influenza HA and NA along with a viral core protein, such as M1,
in insect or mammalian cells resulted in the production of enveloped VLP
vaccines containing influenza HA and NA antigens. The hypothesis behind
an influenza VLP vaccine is that the efficacy of these vaccines is linked to
the particulate, multivalent composition along with correctly folded antigens
with intact biological activities, and that these VLPs are highly immuno-
genic and protective to pathogenic influenza (Haynes, 2009). Infection with
a single vector at a low MOI, comprising of the genes for HA, NA and M1
led to the successful production of influenza VLPs (Haynes, 2009).
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Figure 2.4: Comparison between the structure of influenza virus and
VLP.
In addition, the GAG (group-specific antigen) protein from Human im-
munodeficiency virus (HIV) has been used for VLP production for a vari-
ety of applications. Retroviral GAG protein expression is an efficient VLP
producing method (Chaves et al., 2019). GAG-based influenza VLPs have
been generated that exhibit robust vaccine protection (Haynes et al., 2009;
Cervera et al., 2013, 2017; Gutiérrez-granados et al., 2013; Haynes, 2009;
Venereo-sanchez et al., 2017; Venereo-sánchez et al., 2019).
2.7.3 Influenza VLP as a vaccine candidate
Vaccines are effective in controlling and preventing disease severity, but high
rate of mutations in the viral genome and genetic re-assortment makes the
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production of new vaccines every flu season a necessity. Influenza vaccines
containing live attenuated influenza virus and inactivated virions, both pro-
duced using embryonated chicken eggs, are two common types of influenza
vaccines. The production of these vaccines is time consuming and labor in-
tensive, and also unsuitable against H5N1 viruses which kills the chicken eggs
(Quan et al., 2007). It takes around 3-6 months to produce vaccines using
egg-based technology, thus increasing the cost associated with it. These lim-
itations point to the production of influenza vaccines using cell culture based
technology, which would accelerate the production rate and allow quick re-
sponse to changes in circulating influenza subtypes. A recombinant trivalent
hemagglutinin (rHA) vaccine called FluBlok produced in the IC-BEVS has
emerged as a new alternative to egg-based vaccine (Cox and Hollister, 2009).
The absence of egg-proteins (no cross-contamination) and preservatives, the
presence of three times more HA in FluBlok than egg-based vaccines and the
high purity of antigens makes the production and administration at a higher
dose safe (Cox and Hollister, 2009).
Non-replicative VLPs are a potential vaccine candidate for many viruses
(Pattenden et al., 2005). Antigen presenting cells (APCs) which activate
the adaptive immune system, are responsible for professionally presenting
VLPs (Buonaguro et al., 2006; Sailaja et al., 2007; Kang et al., 2009). Heat
treatment of influenza VLPs, which causes denaturation of the surface HA
glycoprotein, induces a lower titer of intact influenza specific antigens and
provides negligible protection against influenza, and thus indicate the im-
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portance of HA antigen in VLP based vaccines (Quan et al., 2007). There
is evidence that influenza VLPs can induce a cytotoxic T cell response in
mice, thus playing a vital role in protection from heterotypic subtypes of the
influenza virus (Hemann et al., 2019).
Although commercial inactivated and live attenuated human influenza
vaccines against H1N1 virus are immunogenic (Greenberg et al., 2009), there
are certain limitations associated with manufacturing in embryonated eggs
and adverse effect in particular populations (Horimoto and Kawaoka, 2006).
The widespread 2009 pandemic H1N1 virus infection stressed the need for al-
ternative vaccine strategies as opposed to the traditional egg-based method.
A recombinant influenza VLP vaccine comprising of HA, NA and M1 proteins
of the influenza A/California/04/2009 (H1N1) virus was developed using IC-
BEVS. Infection of Sf9 insect cells with a baculovirus coexpressing HA, NA
and M1 proteins resulted in the release of 120 nm influenza VLPs in the
culture medium. When purified these VLPs were found to be morpholog-
ically similar to influenza virions and exhibited biological characteristics of
influenza virus along with HA and NA activities. After being incorporated
in a ferret challenge model, these VLPs produced high-titer serum HA inhi-
bition antibodies for the H1N1 virus and repressed replication of the lower
and upper respiratory tract tissues following H1N1 infection, in addition to
complete clearance of the virus from the ferret lung using only a single 15
µg dose (Pushko et al., 2010). It was shown that intranasally administered
VLPs derived from 1918 pandemic H1N1 virus protected animals against
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lethal homologous and heterologous viruses (Perrone et al., 2009).
To combat avian influenza viruses a recombinant VLP vaccine comprising
of HA, NA and M1 proteins of influenza A/Hong Kong/1073/99 (H9N2)
virus was produced in Sf9 cells using a baculovirus coexpressing the above
three mentioned structural proteins. The VLPs exhibited influenza virus
characteristics including HA and NA activities. When BALB/c mice were
infected with these VLPs, serum antibodies specific for the influenza A/Hong
Kong/1073/99 (H9N2) virus was produced and influenza virus replication
was inhibited. It was thus concluded that VLPs are a potential strategy
for producing vaccines against H9N2 viruses (Pushko et al., 2005). The
licensed trivalent vaccine produced using egg-based technology is efficient in
healthy adults but are not very protective for high risk individuals such as the
elderly and the immunocompromised. It was reported that Sf9 cells-derived
influenza VLPs elicited high immune responses and effective protection in
animal models against seasonal (Bright et al., 2007) and pre-pandemic strains
(Bright et al., 2008). VLP comprising of HA, NA and M1 proteins of the
influenza A/Fujian/411/2002 (H3N2) virus was produced in Sf9 cells using
a baculovirus comprised of the three influenza structural proteins, namely
HA, NA and M1. Intramuscular vaccination of mice or ferrets with these
VLPs in a dose sparing experiment by varying the HA concentration and
comparing the immune responses to those elicited in animals vaccinated with
recombinant HA (rHA) or inactivated whole influenza virions (WIV) revealed




3.1 Cell Line and Maintenance
The clonal isolate 9 of Spodoptera frugiperda, Sf9 cells, were maintained in
Sf-900 III serum free media (GIBCO, Carlsbad, CA, USA) for virus amplifica-
tion and recombinant protein production. The cell cultures were maintained
routinely between 0.6 x 106 and 4.6 x 106 cells/ml in 125 ml capped glass
Erlenmeyer flask at 27◦C on an incubator shaker (VWR International, Mis-
sisauga, ON, Canada) at 130 rpm (revolutions per minute). Cell density and
viability were determined using a Countess II FL hemacytometer (Life Tech-
nologies, Carlsbad, CA, USA) and via trypan blue dye (HiMedia) exclusion
method, respectively.
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3.2 Amplification of Initial Baculovirus Stocks
Sf9 insect cell cultures seeded at 0.6 x 106 cells/ml were allowed to grow to
an exponential phase between 3.5 and 3.8 x 106 cells/ml before being di-
luted back to 2 x 106 cells/ml in fresh Sf-900 III media (GIBCO, Carlsbad,
CA, USA) and infected with eGFP (a green fluorescent protein), mKate2 (a
red fluorescent protein), GAG-GFP (retroviral group specific antigen tagged
with a green fluorescent protein) or HA (influenza hemagglutinin) express-
ing baculovirus, herein referred to as p10GFP, p10RFP, p6.9GAG-GFP and
p6.9HA respectively. The cell cultures infected at an MOI of 0.1 were al-
lowed to propagate until the viability dropped to 70-80% at which point the
cultures were harvested by centrifuging at 1000 x g for 15 minutes to spin
down cell and cell debris. The supernatant from the cultures was collected
and stored at 4◦C to be used in the coinfection experiments.
3.3 Quantification of Infectious Baculovirus
Replication capable virus titers were determined by end point dilution as-
say as described by Reed and Muench (1938) and O’Reilly et al., (1994).
Briefly each well of 96-well plates (Thermo Fisher Scientific, Waltham, Mas-
sachusetts, USA) were seeded with 100 µL of exponentially growing Sf9 cells
or GFP inducing Sf9 cells (GFP-Sf9, provided by a PhD student at the Au-
coin Lab) diluted to 2 x 105 cells/ml with Sf-900 III media and allowed to
attach for 1 hour. Serial dilution of virus stocks were prepared, ranging from
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10−2 to 10−10, using Sf-900 III media. 10 µL of each virus dilution was added
to each well of a row starting with 10−4 dilution, thus resulting in 12 repli-
cates per dilution. The plates were incubated at 27◦C for 5-7 days in a sealed
box with a wet paper towel to prevent the plates from drying out. After the
incubation period, the plates were observed under a fluorescence microscope
and the wells were scored as infected or uninfected based on the fluorescence
of the wells. Each plate was analyzed twice using two filters, green light
for red fluorescence and blue light for green fluorescence, to determine the
titer of both p10GFP and p10RFP. For the p6.9GAG-GFP/p6.9HA virus
stocks, GFP inducing Sf9 cell line was used to detect the combined titer of
the stocks. A detailed calculation of the titers can be found in Appendix
A. The titers obtained from this assay were used to calculate the amount of
virus stock to be added to cell culture to perform an infection at a particular
MOI.
virus amount (ml) =
MOI × number of cells
titer of virus
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Figure 3.1: An overview of the amplification process.
3.4 Design of Dual Stock (Coinfection) Ex-
periments
Sf9 cell cultures at a density of 2 x 106 cells/ml in Sf-900 III media with a
working volume of 35 ml were coinfected, in duplicates, with P3 stocks of
p10GFP (recombinant baculovirus expressing eGFP under the very late p10
promoter) and p10RFP (recombinant baculovirus expressing mKate2 under
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the very late p10 promoter) at a total MOI of 10 (high MOI) or 0.1 (low
MOI). In addition, 2 x 106 Sf9 cells/ml in Sf-900 III media were coinfected,
in duplicates, with P3 stocks of p6.9GAG-GFP (recombinant baculovirus ex-
pressing GAG-GFP under the late promoter p6.9) and p6.9HA (recombinant
baculovirus expressing HA under the late promoter p6.9) at a total MOI of
0.1. The different MOI combinations used are summarized in Tables 3.1,
3.2 and 3.3. Samples were taken at 0, 24, 36, 48, 72 and 84/96 hours
post-infection (hpi).
MOI Ratio MOI p10GFP MOI p10RFP Total MOI
10:0 10 0 10
7:3 7 3 10
5:5 5 5 10
3:7 3 7 10
0:10 0 10 10
Table 3.1: Different MOI combinations used in dual stock experiment at a
total MOI of 10. MOI Ratio refers to the ratio of MOI of p10GFP to MOI
of p10RFP.
Cell density and viability were determined at each of these time points us-
ing a Countess II FL Automated Cell Counter (Life Technologies, Carlsbad,
CA, USA). Samples were centrifuged at 300 x g for 10 minutes, the super-
natant was discarded and cell pellets were resuspended in 2% paraformalde-
hyde solution in phosphate buffered saline (PBS) and kept at 4◦C for approx-
imately 1 hour before dilution with 1x PBS and analysis by flow cytometry.
The controls used were uninfected cultures seeded at the same density as
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the infected cultures and infections with P3 stocks of p10GFP, p10RFP,
p6.9GAG-GFP or p6.9HA. Supernatants containing co-propagated viruses
(p10GFP and p10RFP) were collected from each culture condition (MOI
Ratio) around 70-80% viability as described in Section 3.2 and stored at
4◦C to be used in the first set of co-propagated single infections. For in-
fections with p6.9GAG-GFP and p6.9HA, after harvesting the cultures, the
cell pellets were stored at -80◦C, while the supernatants were stored at 4◦C
with half of it to be used as virus stocks in the first round of co-propagated
single infections and the other half was filtered using a 0.2 µm membrane
filter (VWR International, Mississauga, ON, Canada) and kept at 4◦C for
further analysis.
MOI Ratio MOI p10GFP MOI p10RFP Total MOI
0.1:0 0.01 0 0.01
0.07:0.03 0.07 0.03 0.01
0.05:0.05 0.05 0.05 0.01
0.03:0.07 0.03 0.07 0.01
0:0.01 0 0.01 0.01
Table 3.2: Different MOI combinations used in dual stock experiment at a
total MOI of 0.1. MOI Ratio refers to the ratio of MOI of p10GFP to MOI
of p10RFP.
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MOI Ratio MOI p6.9GAG-GFP MOI p6.9HA Total MOI
0.1:0 0.01 0 0.01
0.07:0.03 0.07 0.03 0.01
0.05:0.05 0.05 0.05 0.01
0.03:0.07 0.03 0.07 0.01
0:0.01 0 0.01 0.01
Table 3.3: Different MOI combinations used in dual stock experiment at a
total MOI of 0.1. MOI Ratio refers to the ratio of MOI of p6.9GAG-GFP to
MOI of p6.9HA.
3.5 Design of Single Stock Experiments
Sf9 insect cells seeded at 2 x 106 cells/ml in Sf-900 III media with 35 ml
working volume were infected with P4 co-propagated stocks obtained from
the previous dual stock (coinfection) experiment at a total MOI of 10 or 0.1.
Sampling was done at 0, 24, 36, 48, 72 and 84/96 hpi.
Cell density and viability were determined using hemacytometer and try-
pan blue dye exclusion method. Samples were prepared as described in Sec-
tion 3.4 to be assessed by flow cytometry. The controls used were unin-
fected cultures at the same density and infections with only P4 p10GFP,
p10RFP, p6.9GAG-GFP or p6.9HA virus stocks as obtained from the previ-
ous single infections. While, the supernatants obtained from this round of
p10GFP/p10RFP co-propagated single infections when the viability dropped
to around 70-80% were collected and stored at 4◦C for future experiments,
the supernatants from p6.9GAG-GFP/p6.9HA co-propagated single infec-
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tions were stored at 4◦C with half of it to be used as the next co-propagated
stocks in the second round of co-propagated single infections and the other
half was filtered using a 0.2 µm membrane filter and kept at 4◦C for further
analysis. Moreover, the cell pellets were stored at -80◦C for determining the
HA activity.
3.6 Flow Cytometry Analysis
A BD FACSCalibur (BD Biosciences, San Jose, CA, USA) was used for
flow cytometry analysis at each of the time points. Green fluorescence was
detected using the FL1 detector, whereas, the red fluorescence was detected
by the FL3 detector. Samples were run using a medium flow rate of 35
µL/min and 10,000 events (each cell is considered an event) were acquired for
each sample. The amplification mode was set to linear for FSC and SSC, and
to logarithmic for FL1 and FL3. The results were acquired using CellQuest
Pro (BD Biosciences, Missisauga, ON, Canada) and analyzed using FlowJo
software (Tree Star, Ashland, OR, USA) and the R programming language.
3.7 Sucrose Cushion Ultracentrifugation
The filtered supernatants obtained from each p6.9GAG-GFP/p6.9HA culture
condition when the viability dropped between 70-80% were concentrated by
ultracentrifugation using a 25% sucrose cushion to remove low density par-
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ticles and semi-purify the VLPs. 25% sucrose solution was prepared by dis-
solving sucrose in chilled 1x NTC buffer (1 M NaCl, 0.2 M Tris-HCl pH 7.4,
50 mM CaCl2). Samples were layered over 1.5 ml of the prepared sucrose
cushion and centrifuged using a Beckman Coulter Optima XPN-100 ultra-
centrifuge (Beckman Coulter, Mississauga, ON, Canada) with SW41 Ti rotor
(Beckman Coulter, Mississauga, ON, Canada) at 26,000 rpm for 1.5 hours at
4◦C. Following the ultracentrifugation, the supernatant was discarded care-
fully and the pelleted virions were resuspended in 2 ml of chilled 1x NTC
buffer. The samples were then shaken at 200 rpm on ice for 20 minutes before
being further purified by a density gradient.
3.8 Iodixanol Density Gradient Ultracentrifu-
gation
Iodixanol gradients were prepared in 14 x 89 mm polyallomer centrifuge
tubes (Beckman Coulter, Mississauga, ON, Canada). Each gradient had six
steps comprising of 60%, 50%, 40%, 30%, 20% and 10% iodixanol in 1x
NTC buffer. Using a pipette, 1.5 ml of each step was layered slowly taking
precautions not to mix the layers. 2 ml of the resuspened virion obtained
by sucrose cushioning was then layered slowly on top of the final 10% step,
followed by a layer of 1ml 1x NTC buffer. Centrifugation was done using
Beckman Coulter Optima XPN-100 ultracentrifuge (Beckman Coulter, Mis-
sissauga, ON, Canada) with SW41 Ti rotor (Beckman Coulter, Mississauga,
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ON, Canada) at 35,000 rpm for 2.5 hours at 4◦C. Following iodixanol den-
sity gradient ultracentrifugation, 1 ml fractions (the fraction obtained from
the top was considered Fraction 1) were collected by puncturing the side of
each centrifuge tube. The weight of the fractions were determined and the
densities were calculated before storing them at 4◦C for further analysis.
3.9 Hemagglutination Assay
Influenza VLPs have an envelope protein called hemagglutinin (HA) that
is capable of binding to sialic acid receptors on cells as well as to erythro-
cytes (red blood cells) thus resulting in the formation of a lattice. This
phenomenon, called hemagglutination, gives an indirect indication of the
presence of influenza virus. The bulk supernatants and cell lysates obtained
at 72, 84 or 96 hpi (depending on the time point at which the culture reached
70-80% viability), in addition to the purified fractions from density gradient
ultracentrifugation, were checked for HA activity by Hemagglutination assay
(HA assay). In particular, 50 µL of 1x PBS was added to each well (except
the first well of each row) of 96-well round-bottom plates. The last row of
each plate was used as a negative control with only 1x PBS in all the wells
and 100 µL of a virus sample was added to the first well of a row. The
virus sample was serially diluted 1:2 (two-fold dilution) across the row with
each row comprising of a different virus having the same dilution pattern. 50
µL of 0.5% chicken red blood cells (RBCs) (Rockland Immunochemicals Inc.
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Limerick, PA, USA) in 1x PBS was added to all the wells of the plates. After
addition of RBCs, the plates were incubated at room temperature overnight.
Following the incubation period, the wells were examined for signs of hemag-
glutination. Formation of lattice or coating of the well by RBCs attached
to virus particles marked the presence of hemagglutination, while the lack
of it was an evidence that there were no virus particles containing HA to
which RBCs could attach and the blood settled to the bottom of the well
as a button or pellet. The HA titer of a virus stock was indicated as the
hemagglutination units (HAU)/50 µL and was equivalent to the reciprocal
of the highest dilution upto which complete hemagglutination was observed.
The HAU/ml of a sample was obtained by multiplying the HAU/50 µL by
20.
3.10 Baculovirus Quantification by Flow Cy-
tometry (SYBR Green Staining)
The baculovirus quantification method was adapted from the paper “Quan-
tification of Baculovirus Particles by Flow Cytometry” (Shen et al., 2002).
Briefly, virus stocks were serially diluted to 10−2 and 10−3 in sterile PBS.
The virus samples were then fixed in 2% paraformaldehyde at 4◦C for 1 hour
to get a final concentration of 0.02%. This was followed by a freeze-thaw
cycle comprising of freezing the samples at -80◦C for 30 minutes and thaw-
ing them for around 5 to 10 minutes in a water bath at 27◦C. The fixed and
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frozen-thawed samples were subjected to permeabilization with 10% Triton
X-100 for 5 minutes to obtain a final concentration of 0.01%. The perme-
abilization step was succeeded by staining with SYBR Green I Nucleic Acid
Gel Stain 10000x (Thermo Fisher, Mississauga, ON, Canada) diluted to 5 x
10−3. The SYBR Green I stained samples were eventually transferred to a
20 well VWR Digital Dry Block Heater (VWR International, Mississauga,
ON, Canada) and incubated in the dark for around 6 minutes at 80◦C. This
was followed by a cooling step in ice before transferring the samples to 5 ml
tubes (VWR International, Radnor, PA, USA) for flow cytometry analysis.
A BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA)
equipped with 15 mW, 488 nm argon-ion laser was used for analysis. Green
fluoroscence of the baculovirus particles was detected using a 530 nm band-
pass filter. The discriminator was set on the green fluorescence (FL1) and
the volatge of photomultiplier was regulated to distinguish between the green
fluorescence from the viral particles and the background. All samples were
run three times for 30 seconds at a medium flow rate of 35 µL/min. The
data obtained was processed using FlowJo software (Tree Star, Ashland,
OR, USA) and the R programming language. For calibration purposes 3 µm
FlowSet fluorospheres (Beckman Coulter, Mississauga, ON, Canada) with a
concentration of 1 x 106 fluorospheres/ml were used. A detailed flow settings
and calculations used for quantification can be found in Appendix C.
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Chapter 4
Repeated propagation of two
baculovirus vectors expressing
GFP or RFP simultaneously in
cell culture at high or low MOI
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4.1 Introduction
The use of the insect cell-baculovirus expression vector system (IC-BEVS)
as a production platform has increased in the past few decades. The BEVS
is widely used for the production of proteins and protein complexes both
industrially and at laboratory scale. One of the crucial questions that form
the foundation of production is the infection strategy to be used. The pros
and cons of the different infection strategies have been debated by many
researchers. While few groups have brought forward the importance of co-
expression, others have proved the requirement for coinfection. From an
industrial point of view, coexpression is always preferred as it reduces the
virus burden and the different possible product combinations upon infection.
One of the main drawbacks associated with coexpression though is the lack of
control on the ratios of different proteins being expressed by a virus to make
a particular product. Infection of insect cells using multiple baculoviruses
(coinfection) has been exploited for production of higher order protein and
protein complexes (Aucoin et al., 2006; Pushko et al., 2005). Although the
choice of infection strategy may seem arbitrary, it has a notable impact on
product development (Aucoin et al., 2006). When the formation of a product
requires multiple genes to be expressed in different proportions, using one (or
more) polycistronic baculovirus carrying the genes for all proteins of interest
may not be fruitful. Also, the level of expression of each protein of inter-
est may vary and not all the genes needs to be expressed at the same level
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(George, 2016). In addition, large baculovirus constructs containing multi-
ple genes of interest maybe unstable (Zhai et al., 2019), thus not helpful for
scale-up. The benefit of using coinfection at a small scale is the additional
degree of freedom to tailor virus ratios by altering the MOI (multiplicity of
infection) of each virus construct. A lot of work has been done on the prop-
agation of viruses at high and low MOI, and the accumulation of defective
interfering particles in culture medium (Kool et al., 1991; Gotoh et al., 2002;
Aucoin et al., 2006), but not much preference has been given to the possibil-
ity of maintaining the ratios during the simultaneous amplification process
of multiple viruses.
The objective of this work was to take advantage of coinfection to explore
different ratios of two virus constructs and track the virus populations over
repeated passaging. For the purpose of this project two baculovirus con-
structs expressing an easily traceable reporter protein, in particular eGFP
(green fluorescent protein, GFP) or mKate2 (red fluorescent protein, RFP),
were amplified together to follow the population distribution of the resulting
co-propagated stocks upon subsequent amplifications. The resultant virus
stocks, hereby known as single or co-propagated stock(s), were used for suc-
cessive infections. Following the coinfection experiment (P3, passage num-
ber of starting stocks) two sets of co-propagated single infection experiments
were run. Two different total MOIs were selected for infection: high MOI
of 10 and low MOI of 0.1, and the entire set of one coinfection and two co-
propagated single infections were run for each chosen total MOI. The aim
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was to see if the virus population/ratio changes or if it is maintained over
repeated amplification so that coinfection can be avoided at industrial scale.
4.2 Results and Discussion
From literature we know that baculovirus infection in cell culture follows a
Poisson distribution. According to Poisson distribution, upon baculovirus
infection each cell can receive one, multiple or no virus vector. In order for
each cell to be infected with at least one virus, cell cultures must be infected
at a MOI > 3, thus resulting in synchronous infection. Infections at a MOI
<< 1 leads to asynchronous infection, where all the cells are not infected
simultaneously. In this work we wanted to see the population distribution
upon repeated propagation at high (> 3) or low (<< 1) MOI.
A schematic of coinfection of Sf9 cells with the two different virus vec-
tors, p10GFP and p10RFP, and the techniques used to track the population
distribution upon infection is shown in Figure 4.1. Following this, the bud-
ded virus comprising of both p10GFP and p10RFP was used for subsequent
amplification, as can be seen in Figure 3.1, and the same techniques were
used for the analysis.
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Figure 4.1: Schematic of the p10GFP and p10RFP infection analysis
techniques.
GFP and RFP produced inside the cell were tracked by flow cytometry. The
budded virus (p10GFP and p10RFP) in the cell culture supernatant, at the
end of the infection cycle was determined by EPDA.
4.2.1 High MOI
It is known from literature that although high MOI is beneficial for protein
production and synchronous infection, for virus amplification it is not deemed
ideal. Despite the fact that high MOIs are known to cause accumulation of
defective interfering particles in cell cultures, we sought to investigate how
the population of two different viruses change via the expression of reporter
proteins (GFP and RFP) when (a) cells are coinfected; and (b) cells are in-
fected with virus resulting from a co-propagated culture. After investigating
different high MOIs (5, 10 and 20), we saw that although there is an im-
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provement from MOI 5 to 10, there is not much difference between MOIs 10
and 20. Thus, we can say that after increasing the MOI to a certain level, it
reaches a saturation point and only increases the virus load in the cultures.
This led us to use a high MOI of 10 for the synchronous infections. The
different MOI combinations of the two virus vectors in the coinfection exper-
iments were selected keeping in mind that we achieve synchronous infection
even at the individual infection level.
4.2.1.1 Flow Cytometry Analysis of Infection
The two easily traceable reporter proteins eGFP (GFP) and mKate2 (RFP)
used in this work were tracked by flow cytometry. As the infection progressed
three distinct populations of cells corresponding to two singly infected pop-
ulations with either p10GFP or p10RFP and a coinfected population were
observed (Figure 4.2). These three populations were gated manually using
the FlowJo software, based on the single infections with only p10GFP or
only p10RFP.
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Figure 4.2: A representation of flow cytometer scatter plots showing
distinct populations of p10GFP+p10RFP coinfected Sf9 cells as
compared to single infected (with either p10GFP or p10RFP) Sf9
cells at 48 hpi at a total MOI of 10.
FL3 corresponds to red and FL1 to green fluorescence. p10GFP:p10RFP is
the ratio of the two viruses used in the coinfection experiment. A certain
percentage of low fluorescent events are at the edge of the chart, which are
not considered for analysis, thus resulting in the total infected populations
to be less than 100%.
If we look at the distribution of populations with repeated passaging,
there is a drop in the percentage of the coinfected population for all the
different culture conditions. The maximum variation in population distri-
bution from P3 to P4 was observed for the cell cultures infected with equal
concentrations of both the viruses (MOI p10GFP:p10RFP 5:5), while the
minimum variation was seen in the cultures infected with higher concen-
tration of p10GFP (MOI p10GFP:p10RFP 7:3). However, the population
distribution between the two co-propagated single infections (P4 and P5)
varied the most for the higher p10GFP infections. Also, it is to be noted
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that the coinfected population shifted towards the lower fluorescence levels
for all the cultures with repeated passaging (Figure 4.3).
Figure 4.3: A representation of flow cytometer scatter plots showing
distinct populations of p10GFP+p10RFP coinfected Sf9 cells at 48
hpi at a total MOI of 10.
FL3 corresponds to red and FL1 to green fluorescence. P3, P4 and P5
refer to the passage number of virus stocks used in the coinfection, and
the first and second co-propagated single infection experiments, respectively.
p10GFP:p10RFP is the MOI ratio of the two viruses used in the coinfection
experiment. The first, second and third panel (top to bottom) represents
the population distribution of only p10RFP, p10RFP+p10GFP and only
p10GFP infected population for the MOI ratios of p10GFP:p10RFP 7:3, 5:5
and 3:7, respectively. A certain percentage of low fluorescent events are at
the edge of the chart, which are not considered for analysis, thus resulting in
the total infected populations to be less than 100%.
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The different cell populations became more prominent around 48 hpi and
were used for further analysis. The percentage of GFP+RFP, GFP and RFP
positive cells upon infection and the intensity of fluorescence expressed by
these cells are based on the three selected populations.
The single infected red population (Percent.FL3, p10GFP:p10RFP 0:10)
decreased by 50%, whereas the single infected green population (Percent.FL1,
p10GFP:p10RFP 10:0) decreased by 22% from P3 to P5. For the coin-
fected populations (Percent.co) the percentage of cells expressing fluores-
cence was higher for the conditions having higher (p10GFP:p10RFP 3:7) or
equal (p10GFP:p10RFP 5:5) p10RFP. There was a 12-30% decrease in all
the coinfected population from P3 to P5 (Figure 4.4). Due to the sensi-
tivity of flow cytometer (overlapping) we did not see similar percentages for
p10GFP:p10RFP 7:3 and 3:7 although they were normalized to have similar
outputs.
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Figure 4.4: Percentage of cells expressing fluorescence at different
time points when infected at a high MOI.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the virus
stocks of p10GFP and p10RFP used in the coinfection experiment, while P4
and P5 are the virus stocks of p10GFP+p10RFP used in the subsequent
co-propagated single infection experiments. Percent.FL1 corresponds to the
percentage of cells expressing green fluorescence, Percent.FL3 is the percent-
age of cells expressing red fluorescence and Percent.co is the population of
cells expressing both green and red fluorescence. The data points shown here
are an average of values for duplicate flasks.
The decrease in green fluorescence is more prominent for the single in-
fection (Mean.FL1, p10GFP:p10RFP 10:0), while for the red fluorescence
(Mean.FL3), the drop is more for the higher p10GFP (p10GFP:p10RFP 7:3)
and only p10RFP (p10GFP:p10RFP 0:10) infections. The intensity of coin-
fected population decreases 1.3-1.6 times from P3 to P4 and 1.1 to 1.5 times
from P4 and P5 (Figure 4.5).
47
Figure 4.5: Intensity of fluorescence at different time points post
infection at high MOI.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the virus
stocks of p10GFP and p10RFP used in the coinfection experiment, while P4
and P5 are the virus stocks of p10GFP+p10RFP used in the subsequent co-
propagated single infection experiments. Mean.FL1 corresponds to the green
fluorescence, Mean.FL3 is the red fluorescence and Mean.co is the combined
fluorescence expressed by the coinfected population. The data points shown
here are an average of values for duplicate flasks.
4.2.1.2 Titer of Virus Stocks
P3 stocks of p10GFP and p10RFP amplified from P2 stocks in Sf9 cell cul-
tures at an MOI of 0.1 had high titers in the order of 108. With repeated
passage at a high MOI of 10 the titers dropped from approximately 6-7 x 108
for P3 to 1-3 x 107 for P6 (Figure 4.6). This is in line with literature, which
represents that the use of high MOI for virus amplification is not ideal.
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Figure 4.6: Titer of baculovirus in cell culture supernatant at 70-80%
viability as obtained by end point dilution assay (amplification at
high MOI).
P3, P4, P5 and P6 refer to the passage number of virus stocks. P3 be-
ing the virus stocks of p10GFP and p10RFP used in the coinfection ex-
periment, while P4, P5 and P6 are the subsequent co-propagated stocks of
p10GFP+p10RFP. The titers plotted are an average of duplicates.
4.2.2 Low MOI
From literature it is known that a low MOI is preferred for virus amplifica-
tion. Infecting cell cultures with a low MOI results in asynchronous infection
where cell growth persists post infection. It is also known that a low MOI
can reduce the passage effect, which is highly undesirable during repeated
amplification. Thus, we wanted to inspect how two virus populations change
by expressing easily traceable reporter proteins, when (a) cells are coinfected;
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and (b) cells are infected with the resultant co-propagated viruses, at a low
MOI. In order to achieve asynchronous infection (MOI << 1), total MOI
of 0.1 is selected, which is a 100 fold drop from the high MOI of 10. The
different MOI combinations of p10GFP and p10RFP in the coinfection ex-
periments, also dropped by 100 fold from the high MOI ones to maintain
consistency.
4.2.2.1 Flow Cytometry Analysis of Infection
Three cell populations corresponding to two single populations infected with
either p10GFP or p10RFP, and a coinfected population were observed with
the advancement of infection (Figure 4.7). Similar to the high MOI in-
fections, the three distinct populations observed here, were gated manually
using the FlowJo software, based on the single infections with only p10GFP
or only p10RFP.
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Figure 4.7: A representation of flow cytometer scatter plots show-
ing distinct populations of Sf9 cells coinfected with p10GFP and
p10RFP in equal ratios, as compared to single infected (with
p10GFP or p10RFP) Sf9 cells at 48 hpi at a total MOI of 0.1.
FL3 corresponds to red and FL1 to green fluorescence. p10GFP:p10RFP is
the ratio of the two viruses used in the coinfection experiment. A certain
percentage of low fluorescent events are at the edge of the chart, which are
not considered for analysis, thus resulting in the total infected populations
to be less than 100%.
As compared to the distinct populations observed for high MOI infec-
tions, the percentage of a single population expressing cells has increased
and the percentage of the coinfected population has dropped for low MOI
infections (Figure 4.9). These populations became more prominent around
48 hpi and used for further analysis. The maximum coinfected population for
each passage is observed for the higher p10RFP infections (p10GFP:p10RFP
0.03:0.07) at 48 hpi. The distribution of the coinfected population did not
vary much between the coinfection and the subsequent co-propagated single
infection for all the coinfected conditions as can be seen in Figure 4.8. With
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progress in the infection cycle, the coinfected population shifted more towards
the red or green fluorescence depending on the condition of the coinfected
cultures.
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Figure 4.8: A representation of flow cytometer scatter plots showing
distinct populations of coinfected Sf9 cells at 48 hpi at a total MOI
of 0.1.
FL3 corresponds to red and FL1 to green fluorescence. P3, P4 and P5 re-
fer to the passage number of virus stocks used in the coinfection, and the
first and second co-propagated single infection experiments, respectively.
p10GFP:p10RFP is the MOI ratio of the two viruses used in the coin-
fection experiment. p10GFP:p10RFP refer to the MOI ratio of the two
viruses used in the coinfection experiment. The first, second and third
panel (top to bottom) represents the population distribution of only p10RFP,
p10RFP+p10GFP and only p10GFP infected population for the MOI ratios
of p10GFP:p10RFP 0.07:0.03, 0.05:0.05 and 0.03:0.07, respectively. A certain
percentage of low fluorescent events are at the edge of the chart, which are
not considered for analysis, thus resulting in the total infected populations
to be less than 100%.
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The single infected red population (Percent.FL3, p10GFP:p10RFP 0:0.1)
exhibited a decrease of around 2.44 times from the coinfection experiment
(P3) to the first round of co-propagated single infections (P4) and an increase
of 1.04 times from P4 to P5 (second round of co-propagated single infections),
whereas the single infected green population (Percent.FL1, p10GFP:p10RFP
0.1:0) showed an almost 1.85 times decrease from P3 to P4 and a 1.72 times
increase from P4 to P5. For the coinfected populations (Percent.co) the
percentage of cells expressing fluorescence is higher for the conditions having
higher (p10GFP:p10RFP 0.03:0.07) or equal (p10GFP:p10RFP 0.05:0.05)
p10RFP. There is a 1.02 times increase in the coinfected population from P3
to P4 and a 1.09-1.48 times drop from P4 to P5. Due to the sensitivity of
the flow cytometer and overlapping nature of the green and red fluorescence
we don’t see similar percentages for p10GFP:p10RFP 0.07:0.03 and 0.03:0.07
even after normalizing the conditions.
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Figure 4.9: Percentage of cells expressing fluorescence at different
time points when infected at low MOI.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the
virus stocks of p10GFP and p10RFP used in the coinfection experiment,
while P4 and P5 are the virus stocks of p10GFP+p10RFP used in the first
and second round of co-propagated single infection experiments respectively.
Percent.FL1 corresponds to the percentage of cells expressing green fluores-
cence, Percent.FL3 is the percentage of cells expressing red fluorescence and
Percent.co is the population of cells expressing both green and red fluores-
cence. The values plotted here are an average of values for duplicate flasks.
The decrease in green fluorescence (Mean.FL1) is more prominent from
the first round of co-propagated single infections (P4) to the second round
of co-propagated single infections (P5) with the highest drop of 2.05 times
for the condition p10GFP:p10RFP 0.03:0.07, while for the red fluorescence
(Mean.FL3) there is an increase of 1.31 times from P3 (coinfection experi-
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ment) to P4 and a drop of 1.61 times from P4 to P5 (Figure 4.10). The
intensity of coinfected population shows a significant decrease of around 3.82
times from P3 to P4 and 1.17 times from P4 to P5.
Figure 4.10: Intensity of fluorescence at different time points post
infection at low MOI.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the virus
stocks of p10GFP and p10RFP used in initial dual stock experiment, while
P4 and P5 are the virus stocks of p10GFP+p10RFP used in co-propagated
single infection experiments. Mean.FL1 corresponds to the green fluores-
cence, Mean.FL3 is the red fluorescence and Mean.co is the combined fluo-
rescence expressed by the coinfected population. The values plotted here are
an average of values for duplicate flasks.
4.2.2.2 Titer of Virus Stocks
P3 stocks of p10GFP and p10RFP amplified from P2 stocks in Sf9 cell cul-
tures at an MOI of 0.1 had titers in the order of 108. With repeated passage
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at a low MOI of 0.1, the titers did not drop drastically from P3 to P5 (Figure
4.11). Additionally, there is an increase in the titer of the P4 co-propagated
stocks. The minimal change in titers over subsequent passaging is indica-
tive of the benefit of using low MOI for virus amplification, as known from
literature.
Figure 4.11: Titer of baculovirus in cell culture supernatant at 70-
80% viability as obtained by end point dilution assay (amplification
at low MOI).
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the
virus stocks of p10GFP and p10RFP used in the coinfection experiment,
while P4 and P5 are the subsequent single stocks of p10GFP+p10RFP. The
titers plotted are an average of duplicates.
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4.3 Conclusions
Coinfection is a necessary strategy as large constructs with multiple genes
maybe unstable and thus not favourable for process scale-up. In addition,
coinfection also comes with the advantage of controlling the ratios of different
viruses to be used for product formation. The main aim of this work was to
track the distribution of two virus populations over repeated passaging by
co-amplifying them at high and low MOIs, and then using the virus resulting
from the coinfected cultures for succeeding infections, such that the use of
coinfection can be eliminated at larger scale.
Although high MOI is known to increase the accumulation of defective
interfering particles (DIPs), known as the passage effect, the aim was to
see if the virus distribution or ratio changes, or is maintained with repeated
passages. The titer of virus stocks kept decreasing over passages when a high
MOI of 10 was used. The titer dropped from higher 108 order to lower 107
order for P3 stocks (used for the coinfection experiment) and P6 stocks (single
stocks obtained from the second round of co-propagated single infections).
Along with the huge reduction in titer over passage number the drop in
viability of cells post infection got delayed by 24 hours for the second round
of co-propagated single infections when MOI of 10 was used (Appendix D,
Figure D:1). In addition, there were changes in the population distribution,
as well as, reduction in the percentage of cells expressing fluorescence and the
intensity of fluorescence from the three distinct populations over subsequent
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amplifications.
From literature, we know that the use of low MOI is preferred for ampli-
fication of viruses as it can minimize the accumulation of DIPs. The titers of
the virus stocks obtained after repeated passaging improved instantly when a
low MOI of 0.1 was used. There were some variations in the replicative virus
titer with passage number but not as drastic as those observed for the high
MOI infections. Also, the coinfected population did not vary much between
the coinfection experiment and the succeeding co-propagated single infection
experiment. However, the intensity of fluorescence showed some decrease
with passage even for low MOI infections. Due to the overlapping nature of
the two fluorescent proteins and the sensitivity of the flow cytometer, a dif-
ferent combination of viruses expressing industrially relevant proteins could
be used to predict the production capacity of the system over passages.
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Chapter 5
Repeated propagation of two
viruses expressing GAG-GFP
or HA proteins simultaneously
in insect cell cultures
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5.1 Introduction
Influenza is an enveloped RNA virus belonging to the Orthomyxoviri-
dae family. The HA (hemagglutinin) glycoprotein found on the surface of
influenza viruses is partly responsible for the infectivity of the virus. HA
is a class I fusion protein acting as both an attachment factor and a mem-
brane fusion protein thus forming a bond between the virus and sialic acid
on the surface of taget cells (Russell et al., 2008). Influenza poses signif-
icant risk of morbidity and mortality connected with seasonal exposure to
continually drifting influenza strains. It is believed that the next influenza
pandemic is on the outlook and it is associated with a new influenza A sub-
type (antigenic drift) (Haynes et al., 2009). Thus, there is a constant need
to improve the flu vaccine to protect against pathogenic influenza strains.
The GAG protein derived from the retrovirus has the ability to self-assemble
and bud at the plasma membrane resulting in the formation of enveloped
non-infectious VLPs (Chaves et al., 2019; Cervera et al., 2013). GAG-based
influenza VLPs containing influenza antigens have been reported to exhibit
robust vaccine protection and suggested applicability towards other respira-
tory viruses (Haynes et al., 2009; Cervera et al., 2013).
Influenza vaccine generation using the influenza antigen(s) presented as
VLPs has attracted a lot of attention (Venereo-sanchez et al., 2017). Well-
assembled VLPs can mimic the original virus from which it is derived, with-
out the presence of virus genome and induce similar immune response in
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the host cells, along with keeping the conformation intact (Zeltins, 2013;
Haynes et al., 2009; Roldão et al., 2010). Egg-based manufacturing technol-
ogy comes with a bundle of limitations including susceptibility to potential
avian influenza pandemic thus threatening global egg supply, being labour
intensive and long production time which would be an issue in case of a pan-
demic. Hence, production of such vaccines using a reliable platform is the
need of the hour.
The need to replace traditional egg-based technology for influenza vaccine
production has led researchers to investigate different production platforms.
The VLPs produced in cell cultures have been reported to elicit broader
immune response as compared to recombinant HA vaccine and whole in-
fluenza inactivated virus (Bright et al., 2007), thus proving to be a candidate
of interest to combat seasonal and pandemic influenza. The IC-BEVS is
a promising alternative for vaccine production. The ease of use, capabil-
ity to carry out post-translational modifications and high protein yield via
infection has made this system a favorable platform for biopharmaceutical
production (Peixoto et al., 2007). This system has been used for the produc-
tion of influenza VLPs leading to the development of influenza vaccines such
as NanoFlu (Novavax) which is expected to initiate Phase III clinical trials in
Fall 2019 (Novavax, 2019). The occurrence of baculovirus budded particles
(BVs), and baculovirus encoded GP64 envelop protein, in VLP preparations
is undesirable for vaccine manufacturing (Chaves et al., 2019). To combat
the issue the GAG gene was expressed in the absence of baculovirus gp64
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gene, which resulted in an improved VLP production method in insect cells
(Chaves et al., 2019).
The work shown in Chapter 4 with the simple virus system of p10GFP
and p10RFP was extended to a more complex industrially relevant system.
The objective of this project was to track the population of two viruses, am-
plified simultaneously, over repeated passage. Two baculovirus constructs,
expressing the retroviral GAG protein fused to eGFP (GAG-GFP) or the HA
protein, were co-amplified to monitor the population distribution of the resul-
tant co-propagated stocks upon successive passaging. The virus stocks from
the coinfected cultures, hereby known as single or co-propagated stock(s),
were used for subsequent infections. Following the coinfection experiment
(P3, passage number of starting stocks), two sets of co-propagated single
infection experiments were run; at a low MOI of 0.1. The aim was to see
if the virus population/ratio changes or if it is maintained over repeated
amplification so that coinfection can be avoided at large scale.
5.2 Results and Discussion
As established in literature, a low MOI was used for repeated virus amplifi-
cation in this work. The MOI ratios used here was kept same as those used
in the p10GFP and p10RFP coinfection experiments at low MOI to maintain
uniformity. A schematic of Sf9 cells coinfected with the two different virus
vectors, p6.9GAG-GFP and p6.9HA, and the techniques used to track the
population distribution upon infection and VLP analysis is shown in Figure
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5.1. Following this, the budded virus comprising of both p6.9GAG-GFP and
p6.9HA was used for subsequent amplification, as can be seen in Figure 3.1,
and the same techniques were used for the analysis. The virus populations
were tracked after each infection. In addition, after harvesting the cultures
at 70-80% viability, the supernatants were purified by sucrose cushioning
and iodixanol density gradient ultracentrifugation; and the purified fractions
were further analyzed for the presence of VLPs.
Figure 5.1: Schematic of the p6.9GAG-GFP and p6.9HA infection
and VLP analysis techniques.
GAG-GFP and HA proteins produced inside the cell were tracked by flow
cytometry. The budded virus (p6.9GAG-GFP and p6.9HA) in the cell cul-
ture supernatant, at the end of the infection cycle was determined by EPDA.
The filtered supernatant obtained at the same time point were purified by
two ultracentrifugation steps. Fractions obtained from the second ultracen-
trifugation were analyzed by HA assay and SYBR green staining.
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5.2.1 Flow Cytometry Analysis of Infection
The progression of infection was tracked by flow cytometry. The Figure
5.2 shows a shift in the population distribution at 48 hpi, when the cul-
ture condition is changed. The gated events are based on the infections
with only p6.9GAG-GFP or p6.9HA, and an uninfected culture. For the
higher (p6.9GAG-GFP:p6.9HA 0.07:0.03) and equal (p6.9GAG-GFP:p6.9HA
0.05:0.05) p6.9GAG-GFP infections, the population of GAG-GFP positive
cells did not change much between the coinfection experiment (P3) and the
first co-propagated single infection experiment (P4). With increasing con-
centration of p6.9HA in the cell culture, the number of GAG-GFP positive
events moved towards the lower fluorescence level, for all the passages. Al-
though, the population distribution is somewhat similar across the passages
for each culture condition, there is a change in the percentage of GAG-GFP
positive cells over subsequent amplifications.
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Figure 5.2: Population of cells expressing green fluorescence at 48
hpi.
P3, P4 and P5 refer to the passage number of virus stocks used in the coin-
fection, and the first and second co-propagated single infection experiments,
respectively. p6.9GAG-GFP:p6.9HA is the MOI ratio of the two viruses used
in the coinfection experiment. The first, second and third panel (top to bot-
tom) represents the population distribution for the MOI ratios of p6.9GAG-
GFP:p6.9HA 0.07:0.03, 0.05:0.05 and 0.03:0.07, respectively. The vertical
line separates the population distribution on the left and right hand side of
each chart. The population on the left hand side of each chart corresponds
to an uninfected or only p6.9HA infected population, whereas that on the
right hand side represents a p6.9GAG-GFP infected or a coinfected popula-
tion. A small percentage of low fluorescent events (cells) are at the edge of
the chart, which are not considered for analysis, thus resulting in the total
infected populations to be less than 100%.
The single p6.9GAG-GFP infection (Percent.FL1, p6.9GAG-GFP:p6.9HA
0.1:0) showed negligible change with passage number. For the coinfected con-
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ditions the percentage of cells expressing green fluorescence (Percent.FL1)
dropped from P3 (coinfection experiment) to P4 (first co-propagated sin-
gle infection experiment) especially for the higher (p6.9GAG-GFP:p6.9HA
0.03:0.07) and equal (p6.9GAG-GFP:p6.9HA 0.05:0.05) p6.9HA culture con-
ditions and increased slightly from P4 to P5 (second co-propagated single
infection experiment) (Figure 5.3).
Figure 5.3: Percentage of cells expressing green fluorescence at
different time points post infection with p6.9GAG-GFP and/or
p6.9HA baculovirus.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the
virus stocks of p6.9GAG-GFP and p6.9HA used in the coinfection exper-
iment, while P4 and P5 are the virus stocks of p6.9GAG-GFP + p6.9HA
used in first and second rounds of co-propagated single infection experiments
respectively. Percent.FL1 corresponds to the percentage of cells expressing
green fluorescence. The plotted data points are an average of values for
duplicate flasks.
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For the single p6.9GAG-GFP infection (p6.9GAG-GFP:p6.9HA 0.1:0),
the green fluorescence (Mean.FL1) portrayed an increase of 1.05 times from
P3 to P4 and a drop of 1.12 times from P4 to P5. However, the intensity
of green fluorescence of the coinfected conditions decreased from P3 and P5
(Figure 5.4).
Figure 5.4: Intensity of green fluorescence at different time points
post infection with p6.9GAG-GFP and/or p6.9HA baculovirus.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the virus
stocks of p6.9GAG-GFP and p6.9HA used in the coinfection experiment,
while P4 and P5 are the virus stocks of p6.9GAG-GFP + p6.9HA used in
the co-propagated single infection experiments. Mean.FL1 corresponds to
the green fluorescence of the GAG-GFP positive cells. The plotted data
points are an average of values for duplicate flasks.
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5.2.2 Titer of Virus Stocks
P3 stocks of p6.9GAG-GFP and p6.9HA were amplified at a low MOI of 0.1
from P2 stocks in Sf9 cell cultures and were used as the starting virus stocks
for the coinfection experiment. Since the HA did not have a fluorescent tag,
the replicative titer of the virus stock by end point dilution assay (EPDA)
could not be determined using Sf9 cells. Thus, the total replicative virus
titer (by EPDA) after each infection was determined by infecting GFP in-
ducing Sf9 cell line (GFP-Sf9), which was kindly provided and validated by
Mark Bruder (PhD student at the Aucoin Lab). Serial passaging of the re-
sultant co-propagated stocks did not portray much variation among different
passages (Figure 5.5). There is a minimal fluctuation in titers of the virus
stocks obtained from the Sf9 cell cultures coinfected with p6.9GAG-GFP and
p6.9HA. This variation could be due to the variability associated with the
end point assays.
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Figure 5.5: Titer of infectious GAG-GFP/HA expressing bac-
ulovirus in cell culture supernatant harvested at 70-80% viability
as obtained by end point dilution assay.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the virus
stocks of p6.9GAG-GFP and p6.9HA used in the coinfection experiment,
while P4 and P5 are the subsequent co-propagated stocks of p6.9GAG-GFP
+ p6.9HA. The titers plotted are an average of duplicates.
5.2.3 Analysis of fractions
The filtered supernatants obtained from each infection at 70-80% culture
viability were concentrated by ultracentrifugation using a 25% sucrose cush-
ion, followed by iodixanol density gradient ultracentrifugation to purify the
virus-like particles. The density, HA activity and baculovirus particle con-
centration of each fraction from the ultracentrifuge purified density gradient
of each culture condition after every infection were examined. The different
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steps followed to purify the influenza VLPs are shown in Figure 5.6.
Figure 5.6: A schematic of the steps followed to obtain ultracen-
trifuge purified fractions.
HA assay is used to determine the presence of influenza virus/VLPs con-
taining the HA protein. The highest HA activity was observed for the ultra-
centrifuge purified fractions 5 or 6 for each culture condition and remained
consistent with repeated passaging (Figure 5.7). That being said, the HA
activity of the fractions obtained from the coinfected cultures dropped by a
factor of 2 from P3 to P5, and for the single p6.9HA infection it dropped by a
factor of 2 from P3 to P4 but did not change from P4 to P5. HA activity was
completely absent for all the fractions obtained from single p6.9GAG-GFP
infections (p6.9GAG-GFP:p6.9HA 0.1:0) and the two least dense fractions (1
and 2) for all the other MOI ratios used. This was constant over the coinfec-
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tion and both the co-propagated single infection experiments. Although, the
HA activity of the fractions reduced with passage number, it is still consid-
ered high. Even though it can’t be deduced with confidence, the variability
maybe due to the accumulation of defective particles which begins the repli-
cation cycle but cannot complete it, thus producing lesser VLPs containg
the HA. Also, as mentioned by George (2016) some of the HA activity gets
lost in the ultracentrifugation step. The densities of the highest HA activity
fractions (5 or 6) for the different conditions (MOI Ratios) varied between
1.09 to 1.19 g/ml for P3 (coinfection experiment), 1.10 to 1.22 g/ml for P4
(first round of co-propagated single infections) and 1.10 to 1.24 g/ml for P5
(second round of co-propagated single infections).
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Figure 5.7: HA activity of ultracentrifuge purified fractions.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the virus
stocks of p6.9GAG-GFP and p6.9HA used in the coinfection experiment,
while P4 and P5 are the virus stocks of p6.9GAG-GFP + p6.9HA used in
the co-propagated single infection experiments. The plotted data points are
an average of duplicate values.
The use of a nucleic acid dye to stain the viral particles and then taking
advantage of the fluorescence to determine the baculovirus particle concentra-
tion by flow cytometry provided to be a fast and easy technique (Shen et al.,
2002). Particle counts (baculovirus particles/ml) revealed the maximum bac-
ulovirus particle concentration was observed from fractions 5 to 8 with the
peak at fraction 6 for most of the conditions (Figure 5.8). The only three
exceptions were for the P3 higher p6.9GAG-GFP (p6.9GAG-GFP:p6.9HA
0.07:0.03), P4 only p6.9GAG-GFP (p6.9GAG-GFP:p6.9HA 0.1:0) and P5
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only p6.9HA (p6.9GAG-GFP:p6.9HA 0:0.1) where the peak was seen in frac-
tions 7, 5 and 5 respectively. However, it is to be noted that the density of
P4 only p6.9GAG-GFP fraction 5 is same as its corresponding P5 fraction
6; and the densities of P3 higher p6.9GAG-GFP fraction 7 and P5 only
p6.9HA fraction 5 are quite similar to those of their corresponding fraction
6. Hence, we can say that the highest baculovirus particle concentration
was observed for the fractions with the same densities, or the highest con-
centration of baculovirus particles was always observed at a particular den-
sity. Although, the peak baculovirus particle concentration did not show a
prominent variation between passage numbers for the higher p6.9GAG-GFP,
visible changes were observed for the equal and higher p6.9HA conditions.
Also, the peak concentration for the coinfected conditions varied between
3.87E + 07 (p6.9GAG-GFP:p6.9HA 0.07:0.03, Fraction 7, P4) to 6.32E +
07 (p6.9GAG-GFP:p6.9HA 0.05:0.05, Fraction 6, P5) with passage number.
Since the other fractions (1-4 and 9-12) did not have a high baculovirus parti-
cle concentration they were dropped. Nevertheless, baculovirus was detected
in all the fractions in varying concentrations.
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Figure 5.8: Baculovirus particle concentration of ultracentrifuge pu-
rified fractions.
P3, P4 and P5 refer to the passage number of virus stocks. P3 being the virus
stocks of p6.9GAG-GFP and p6.9HA used in the coinfection experiment,
while P4 and P5 are the virus stocks of p6.9GAG-GFP + p6.9HA used in
co-propagated single infection experiments. The plotted data points are an
average of duplicate values.
A detailed information on the density gradient ultracentrifuge purified
fractions from each infection over subsequent passages can be seen in Ta-
ble 5.1. The maximum baculovirus particle concentration of the highest
peak were quite comparable among the coinfected conditions for each pas-
sage. The densities do not vary much over passages and are also similar for
the different conditions. In addition, the fraction expressing the highest HA
activity exhibited the highest baculovirus particle concentration with a few
exceptions. These results give away that although density gradient ultracen-
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trifugation can be a useful step in the VLP purification process, it is not the
most effective method to purify VLPs from baculovirus.
Table 5.1: Comparison of density, HA activity and baculovirus particle con-








































0.1:0 P3 1.02 to 1.41 8.55E+06 1.14 6 N/A N/A
0.1:0 P4 0.95 to 1.37 3.24E+07 1.10 5 N/A N/A
0.1:0 P5 1.04 to 1.39 4.20E+07 1.10 6 N/A N/A
0.07:0.03 P3 1.03 to 1.37 4.25E+07 1.11 7 20480 6
0.07:0.03 P4 0.99 to 1.39 3.87E+07 1.22 6 10240 6
0.07:0.03 P5 0.94 to 1.37 4.44E+06 1.15 6 5120 6
0.05:0.05 P3 1.03 to 1.39 4.95E+07 1.11 6 20480 6
0.05:0.05 P4 1.06 to 1.28 4.01E+07 1.16 6 10240 6
0.05:0.05 P5 1.07 to 1.41 6.32E+07 1.10 6 5120 6
0.03:0.07 P3 0.96 to 1.33 5.63E+07 1.19 6 20480 5
0.03:0.07 P4 1.00 to 1.39 4.45E+07 1.16 6 5120 6
0.03:0.07 P5 1.07 to 1.35 5.09E+07 1.24 6 5120 6
0:0.1 P3 1.09 to 1.36 1.55E+07 1.09 6 10240 6
0:0.1 P4 1.01 to 1.43 1.76E+07 1.16 6 5120 6
0:0.1 P5 0.94 to 1.31 3.57E+07 1.04 5 5120 6
5.3 Conclusions
The importance of selecting an infection strategy has been debated time and
again by different researchers. In this work, not only did we take advantage of
the flexibility provided by coinfection at small scale, but also tried to explore
an amplification strategy that could be used with some modifications to avoid
the application of coinfection at the large scale. Amplifying different viruses
together at lab scale helps to control the ratio of each protein required for
product formation, and the resulting stocks from the coinfected cultures can
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be used for successive infections. Based on the results from Chapter 4, it
was concluded that using a high MOI for repeated passaging would lead to
significant drops in replicative virus titer. Thus, a low MOI of 0.1 was selected
for the repeated amplification of industrially relevant proteins: GAG-GFP
and HA.
The infectious virus titer, as determined by end point dilution assay, did
not vary much over repeated passaging for the co-propagated stocks. Since,
the GAG was fused to GFP, its fluorescence was tracked by flow cytome-
try. The drop in GAG-GFP positive cells and intensity of green fluorescence
over passage for the coinfected conditions could be due to more population
being coinfected with p6.9GAG-GFP and p6.9HA, but that can’t be said
with certainty as the distribution of the coinfected only population is not
known separately. Following the influenza VLP purification steps, the ultra-
centrifuge purified fractions showed high HA activity with a two factor drop
from P3 to P5, which maybe due to loss over repeated amplification; and bac-
ulovirus was detected in varying concentrations in all the fractions. Overall
from the results, it was observed that the use of low MOI could help to
sustain the virus distribution over subsequent amplifications. Nevertheless,
ultracentrifugation alone does not have the resolution to separate baculovirus
from VLPs. Thus, in order to purify the VLPs for any biopharmaceutical






The main aim of this work was to track the population distribution over
repeated propagation of multiple viruses simultaneously in insect cell culture
at high or low MOI, so that coinfection can be avoided at industrial scale.
Two virus vectors, p10GFP and p10RFP, expressing GFP and RFP respec-
tively, were used to establish a baseline for repeated virus amplification at
high and low MOI. It was found that using a high MOI changes the virus
population, as well as results in drastic drop in virus titers over subsequent
passages. When a low MOI was used, the population distribution and the
virus titers did not change drastically with repeated amplification.
The use of low MOI for virus amplification has been well established
in literature. For repeated simultaneous propagation of multiple viruses in
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insect cell culture a low MOI should be used, which is also known to minimize
the passage effect.
Using only a low MOI alone won’t be sufficient to combat the issue of
passage effect and other techniques need to be implemented to reduce the
accumulation of these interfering particles. One such way can be the use of
genetic engineering to eliminate/modify the genes responsible for the occur-
rence of DIPs.
Also, different reporter proteins that do not overlap can be used to track
the virus populations over repeated passaging.
Based on these results, low MOI was used for the repeated propagation
of a complex system of virus vectors, p6.9GAG-GFP and p6.9HA, expressing
the proteins GAG-GFP and HA, respectively. As expected, the titers showed
minimal variation with passages, in addition to sustained population distri-
bution observed over at least one passage. However, following the influenza
VLP purification procedure, it was found that baculovirus was present in
varying concentrations in all the ultracentrifuge purified fractions.
In order to produce VLPs for therapeutic or biopharmaceutical applica-
tions a more robust purification system needs to be implemented. It has been
established that sucrose cushioning and/or density gradient ultracentrifuga-
tion does not have the resolution to completely purify or separate VLPs
from baculovirus. Additional purification techniques such as ion exchange
chromatography and cellulose membrane-based steric exclusion chromatog-
raphy (Lothert et al., 2019) can reduce baculovirus contamination in VLP
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preparations.
Moreover, modification of the baculovirus genomes by deleting genes that
are known to cause/increase baculovirus presence in VLP samples can im-
prove VLP production in insect cells (Chaves et al., 2019).
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Appendix A
End Point Dilution Assay
The end point dilution assay (EPDA) technique is based on the Tissue Cul-
ture Infectious Dose 50 (TCID50) assay (Reed and Muench, 1938). TCID50
is the virus dose that causes 50% of the culture to be infected by a virus sam-
ple. Titers are calculated by using equations outlined by King and Possee,
1992.




where A is the percent response greater than 50% and B is the percent
response less than 50%.
Equation A-2. Calculation of TCID50 dose:-
The dose that would give a 50% response is calculated as:
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log10(TCID50) =(log of the dilution giving a response greater than 50%) - (PD)









The hemagglutination assay or HA assay is based on the agglutination of
red blood cells in the presence of the influenza virus envelope protein HA
(hemagglutinin). The reciprocal of the last virus dilution in a row without
the occurrence of a pellet or button at the bottom of the well represents the
hemagglutination units (HAU) per 50 µL. In order to achieve HAU/ml, the
HAU/50 µL is multiplied by 20.
If the last agglutination was observed for the dilution 1:256, then the HA





The following settings were used to analyze samples in the BD FACSCalibur
flow cytometer.





Samples were run at a medium flow rate of 35 µL/min for 30 seconds.
The following equation was used to determine the concentration of viral
particles using the gated events.
100
Equation C-1. Viral particle concentration:-
viral particle concentration = Cv ×D × 1000× 50000
Cf × V ol
where
Cv, Cf are the particle counts for viral particles and FlowSets respectively.
D is the dilution rate of viral solution.
Vol is the volume of diluted viral solution used for sample preparation.
1000 is the final volume of each sample.
50000 is the particle concentration of diluted FlowSet.
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Appendix D
Viability of Sf9 Cells Post
Infection
Cells were monitored at different time points post infection to assess their
progression. When the cultures were infected at an MOI of 10 with p10GFP
and p10RFP, it resulted in synchronous infection. The viability of the cell
cultures kept on decreasing as the infection progressed with 70-80% viability
being achieved at 72 hpi for P3 and P4, and at 96 hpi for P5.
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Figure D.1: Sf9 cells infected at a total MOI of 10:
The viability of the infected cell cultures are shown over the duration of an
infection at MOI 10. P3, P4 and P5 refer to the passage number of virus
stocks used in successive experiments.
Infection at a low MOI of 0.1 with p10GFP and p10RFP, resulted in
asynchronous infection. The cultures followed a similar trend for viability
with the exception of viability drop between 70-80% at 84 hpi when infected
with P4 co-propagated stocks.
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Figure D.2: Sf9 cells infected at a total MOI of 0.1:
The viability of the infected cell cultures are shown over the duration of an
infection at MOI 0.1.
As expected, a low MOI infection with p6.9GAG-GFP and p6.9HA re-
sulted in asynchronous infection. The cultures followed a similar trend for
viability with the exceptions of viability drop between 70-80% at 84 hpi when
infected with P4 co-propagated stocks, and at 72 hpi for the single (p6.9GAG-
GFP:p6.9HA 0:0.1) and higher (GAG-GFP:HA 0.03:0.07) p6.9HA conditions
when infected with P5 single stocks.
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Figure D.3: Sf9 cells infected with p6.9GAG-GFP and p6.9HA bac-
uloviruses at a total MOI of 0.1:
The viability of the infected cell cultures are shown over the duration of an
infection at MOI 0.1. P3, P4 and P5 refer to the passage number of virus
stocks used in subsequent experiments.
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